The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...
Wars and political shocks are currently commanding attention, but history demonstrates markets respond to consequences, not noise, with a remarkable ability to trade through turmoil.